Atara Biotherapeutics Highlights Next-Generation and Off-the-Shelf, Allogeneic CAR T Technologies and Pipeline
“Atara is building a leading next-generation and off-the-shelf, allogeneic CAR T pipeline,” said
The event featured next generation CAR T experts:
- Michel Sadelain, M.D., Ph.D., Director,
Center for Cell Engineering, and Head, Gene Expression and Gene Transfer Laboratory, Memorial Sloan Kettering Cancer Center(MSK) Marco Davila, M.D., Ph.D., Associate Attending Physician, Department of Blood & Marrow Transplantationand Cellular Immunotherapy Medical Director, Cell Therapy Facility, Moffitt Cancer Center
Dr. Sadelain described CAR T technologies including novel co-stimulatory domains modified to generate more physiologic signaling, reduce exhaustion, improve persistence and unlock the solid tumor microenvironment. Atara and MSK are collaborating to develop next-generation CAR T immunotherapies using several of these innovative CAR T technologies.
Dr. Davila’s presentation focused on developing promising CAR T immunotherapies for patients with AML and B cell malignancies in collaboration with Atara using modified co-stimulatory subdomains designed to improve persistence and reduce T cell exhaustion.
Dr. Berger presented results for an EBV.CD19.28z CAR T that demonstrated high CAR transduction, increased frequency of central memory T cell phenotype, specific and selective CD19 activity, low levels of off-target alloreactivity and strong antigen-specific proliferation and persistence. These findings establish feasibility for engineering EBV-specific T cells by leveraging next-generation CAR technologies, and support further development as an off-the-shelf, allogeneic, CAR T platform to generate IND clinical candidates. He concluded by describing Atara’s CAR T preclinical pipeline, including four oncology programs progressing toward IND.
A webcast replay of the Atara CAR T Breakfast Teach-In can be accessed on the Investors and Media section of Atarabio.com for 30 days following today’s live event.
This press release contains or may imply "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. For example, forward-looking statements include statements regarding: the Company’s ability to develop next generation and off-the-shelf, allogeneic CAR T immunotherapies; the Company’s ability to advance programs, including next-generation off-the-shelf CAR T programs, using CAR T technologies; the opportunities to improve outcomes, expand to earlier lines of therapy and address areas of high unmet need; and generation of IND clinical candidates. Because such statements deal with future events and are based on Atara Biotherapeutics' current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Atara Biotherapeutics could differ materially from those described in or implied by the statements in this press release. These forward-looking statements are subject to risks and uncertainties, including those discussed in Atara Biotherapeutics' filings with the Securities and Exchange Commission (
INVESTOR & MEDIA CONTACTS:
Source: Atara Biotherapeutics, Inc.